Flamingo Therapeutics, Inc., a biotechnology organization spearheading RNA-focusing on treatments in oncology, today declared that it has gone into a concurrence with Ionis Pharmaceuticals to foster RNA-designated treatments to treat different types of malignancy. This union is an extension of a current cooperation with Ionis on the FLAME™ disclosure motor, following Flamingo’s Series A financing in 2020.
The understanding and revelation collusion will use Flamingo’s profound mastery in oncology and long non-coding RNAs (lncRNAs) in mix with Ionis’ aptitude in RNA-designated drug disclosure and improvement to propel applicants against targets considered undruggable with conventional methodologies. Flamingo’s pipeline will incorporate three clinical-stage programs from Ionis, inhibitors of STAT-3, Androgen Receptor (AR) and IRF4, and one preclinical-stage program that objectives MALAT1, an all around portrayed lncRNA target. Flamingo will likewise propel its restrictive revelation motor, FLAME (Flamingo LncRNA Antisense Mining Engine), that tends to lncRNAs, an enormous and undiscovered class of infection causing focuses inside the dim matter of the human genome.
“We’re excited to fortify our relationship with Ionis who has been at the front line of RNA-designated treatment for a very long time,” said Michael Garrett, Chief Executive Officer of Flamingo. “We accept the blend of Ionis’ initiative in RNA and our state of the art lncRNA disclosure motor will grow the chances for applying RNA-designated ways to deal with oncology.
I would like to receive information from suppliers sponsoring this content and willing to share the information above with business book 25.SEND
“We are satisfied that Flamingo is utilizing their center qualities in creating novel malignancy medications to progress inventive Ionis-found oncology treatments where there is a neglected need,” said Brett P. Monia, Ph.D., Ionis’ CEO.
Regarding the collusion, Rob MacLeod, Ph.D., VP, Oncology Research and Development of Ionis, will fill in as Chief Scientific Officer of Flamingo. Under the conditions of the arrangement, Ionis is qualified to get achievement installments and eminences on future item deals of the STAT3, AR, IRF4 and MALAT1 programs. Flamingo holds full rights to its FLAME stage and all lncRNA programs outside of MALAT1.
Flamingo Therapeutics was established by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners and PMV, in light of spearheading work drove by Professor Jean-Christophe Marine (VIB-KU Leuven), Professor Pieter Mestdagh (Ghent University) and Professor Arul Chinnaiyan (University of Michigan). These logical groups kicked off something new on non-coding RNA qualities in malignancy and were among quick to show a job for lncRNAs as sickness drivers in oncology.
ABOUT FLAMINGO THERAPEUTICS
Flamingo is spearheading RNA-designated treatments for oncology with cutting edge sciences. Flamingo has the most developed antisense RNA-focusing on oncology portfolio with three clinical projects focusing on undruggable record factors and join variations. To help and extend its pipeline, Flamingo has an exclusive revelation motor, FLAME™ (Flamingo LncRNA Antisense Mining Engine), that tends to lncRNAs, an enormous and undiscovered class of infection causing focuses inside the “dull matter” of the human genome. The Company was established in 2020 dependent on spearheading work in the field of lncRNAs in oncology with our scholarly accomplices at VIB, KU Leuven, Ghent University and the University of Michigan. Flamingo has a disclosure union with Ionis Pharmaceuticals and is upheld by notable biotechnology financial backers Kurma Partners and PMV. The organization is settled in Belgium with extra tasks in San Diego, CA.
